Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 17/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26083464 | 0.86 | CACNA1H (0.58) | CACNA1HCACNA1ICACNA1G | |
| SCHEMBL26082026 | 0.85 | CACNA1H (0.47) | CACNA1HCACNA1ICACNA1G | |
| SCHEMBL26083567 | 0.78 | KMT2A (0.43) | CACNA1HCACNA1ICACNA1GKDM4E | |
| SCHEMBL26082038 | 0.78 | CACNA1H (0.39) | CACNA1HCACNA1ICACNA1G | |
| SCHEMBL26082041 | 0.78 | CACNA1H (0.39) | CACNA1HCACNA1ICACNA1G | |
| SCHEMBL26081952 | 0.78 | KMT2A (0.43) | CACNA1HCACNA1ICACNA1GKDM4E | |
| SCHEMBL26082338 | 0.76 | CACNA1I (0.48) | CACNA1HCACNA1ICACNA1GPSMB8PSMB5 | |
| SCHEMBL26082341 | 0.75 | CACNA1I (0.57) | CACNA1HCACNA1ICACNA1G | |
| SCHEMBL26083134 | 0.74 | CACNA1H (0.66) | CACNA1HCACNA1ICACNA1G | |
| SCHEMBL26104660 | 0.72 | CACNA1H (0.44) | CACNA1HCACNA1ICACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192687-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |